Clinical reference Biomarker Directory
Back to directory

Cytosolic Beta-Glucosidase

Emerging

GBA3/cytosolic beta-glucosidase deficiency is a benign polymorphism, distinct from the disease-associated lysosomal GBA enzyme.

Also known as GBA3 cytosolic beta-glucosidase klotho-related protein
In plain language

This enzyme is genetically distinct from a similarly-named enzyme involved in a well-known disease (Gaucher disease). Missing this particular enzyme doesn't seem to cause any health problems, making it more of a genetic curiosity than something doctors test for clinically.

Biomarker & context

Cytosolic beta-glucosidase, encoded by the GBA3 gene, is an enzyme involved in breaking down certain glycoside compounds; it's distinct from the lysosomal GBA enzyme implicated in Gaucher disease and Parkinson's disease risk.

What it indicates

GBA3 deficiency is generally considered a benign genetic polymorphism without clear disease association, in contrast to its more clinically significant lysosomal cousin GBA.

Diagnosis & clinical testing

GBA3 status can be determined via genetic testing, though this is done primarily in research or pharmacogenomic contexts rather than for any clinical diagnostic purpose.

Guiding treatment

There is no treatment indication associated with GBA3 status, since deficiency doesn't cause recognized disease; it remains more of a research/pharmacogenomic curiosity than an actionable clinical biomarker.

Clinical significance

More of a research and pharmacogenomic curiosity than an actionable clinical biomarker at this time.

References
  1. General biochemistry/genetics reference literature distinguishing GBA3 (cytosolic beta-glucosidase) from GBA (lysosomal glucocerebrosidase).